Previous close | 2.8600 |
Open | 2.8600 |
Bid | 2.9900 x 100 |
Ask | 3.1200 x 400 |
Day's range | 2.8100 - 3.2200 |
52-week range | 2.7000 - 70.0000 |
Volume | |
Avg. volume | 286,937 |
Market cap | 15.044M |
Beta (5Y monthly) | 0.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | -35.6200 |
Earnings date | 21 May 2024 - 28 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.00 |
Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates. Recent Highlights Announced plans to commercialize the T2Lyme Panel in the third quarter of 2024 as a laboratory developed tes
LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch plans and provide additional business updates before market open on Wednesday, March 20, 2024 beginning at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by
Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genesLEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the publication of a new study highlighting the clinical benefits and performance of real-world use of the T2Resistance® Panel in The Journal of Clin